sglt2 inhibitors and glp-1 receptor agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application The Role of SGLT 2

To evaluate the incidence of MACE-4 events in patients treated with tirzepatide compared to the control group, a meta-analysis was conducted using data from 7778 patients enrolled in the SURPASS-4 study, SURPASS Clinical Trails Program (which includes 7 randomized clinical trials), and SURMOUNT-1

5 Phase 1

About one in three Americans said they felt better about their bodies and more comfortable wearing different types of clothing compared to when they were at a higher weight

However, 2026 has brought exciting new advancements

Saxenda runs more than $1300 per month for the uninsured

In one study, microdosing GLP-1s supported moderate weight loss of up to 10 pounds over 40 weeks in participants. MICRODOSING GLP-1 BENEFITS Do More, Age Less Modulated inflammatory pathways in clinical trials. Studies found a reduced risk of cognitive decline Supported cardiovascular health in clinical trials Improved mitochondrial function and oxidative stress in clinical trials Low doses reduced side effects in clinical trials Supported moderate weight loss of up to 10 pounds over 40 weeks in one study *See studies cited below